H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00

Mizuho initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $34.00

Jefferies initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $27.00

TD Cowen initiated coverage of Enliven Therapeutics with a rating of Outperform

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)

8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, pos

BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference taking place September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target th

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical trial evaluating ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in HER2+ MBC and CRC Strong balance sheet with $312 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generat

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:  Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 5Time: 8:30 a.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, June 10Time: 3:20 p.m. ET Both fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventh

Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the first quarter ended March 31, 2024, and provided a business update

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminib ELVN-001 was well tolerated with no ≥ Grade 3 treatment-related non-hematologic toxicities reported  Company to host virtual event with Key Opinion Leaders at 8:00 AM ET Today BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of n

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape. ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML. The event will feature leading CML investigators and hematolog

Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for ELVN-001 and ELVN-002 Company to host an event with KOLs on April 11, 2024, to discuss initial proof of concept data from a Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinas

Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in combination with trastuzumab in patients with HER2+ metastatic breast cancer and colorectal cancer received U.S. FDA clearance Strong balance sheet, closing the year with $253 million in cash, cash equivalents and marketable securities BOULDER, Colo., March 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

Baird analyst Colleen Kusy initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating and announces Price Target of $32.

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent.

Thursday, Enliven Therapeutics Inc (NASDAQ:ELVN) released proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs). ELVN-001 is a small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML. “We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, Chief Medical Officer of Enliven.  Related Co

Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ:RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NA

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose sharply during Thursday’s session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia. Enliven Therapeutics shares surged 26% to $24.97 on Thursday. Here are some other big stocks recording losses in today’s session. Rallybio Corporation (NASDAQ:RLYB) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Alpine Immune Sciences, Inc. (NASDAQ:ALPN) jumped 36.6% to $64.25

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminibELVN-001 was well tolerated with no ≥ Grade 3 treatment-related non-hematologic toxicities reported Company to host virtual event with Key Opinion Leaders at 8:00 AM ET TodayBOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-gener

Mizuho Securities initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN), a clinical-stage precision oncology company focused on discovering and developing next-generation small molecule kinase inhibitors. The company’s lead product, ELVN-001, is under development for Chronic myelogenous leukemia (CML), a slow-progressing blood cancer that begins in the bone marrow. Thursday, Enliven Therapeutics will host a webcast to discuss initial proof of concept data on ELVN-001. Additional Phase 1 data is expected in 2025, but Mizuho expects late 2024 could also be possible. Mizuho writes that the CML tyrosine kinase inhibitors (TKI) market is established, ~$13 billion-$14 billion wo

Mizuho analyst Salim Syed initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Target of $34.

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape. ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML. The event will feature leading CML investigators and hematology care experts, Professor Michael Mauro, M.D., from Me